Form 4: EcoR1 Capital Increases Stake in Zymeworks Inc. Through Recent Stock Purchases

EcoR1 Capital, along with related entities, has increased its holdings in Zymeworks Inc. through a series of stock purchases.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have reported changes in their beneficial ownership of Zymeworks Inc. common stock.
• On May 15, 2025, Qualified Fund purchased 46,405 shares at a price of $11.4308 per share, bringing their total holdings to 16,758,589 shares.
• On May 19, 2025, Qualified Fund purchased an additional 5,550 shares at $11.7821 per share, increasing their total to 16,764,139 shares.
• EcoR1 Capital, as the investment advisor to the Funds, may be deemed to indirectly beneficially own these shares, and Mr. Nodelman, as the control person of EcoR1, may also be deemed to indirectly beneficially own them.
• The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.

Sentiment

Score: 6

Explanation: The document indicates increased investment by a major shareholder, which is generally a positive sign, but it's a routine filing and doesn't provide enough information to strongly indicate a bullish outlook.

Positives

• Increased investment by EcoR1 Capital may signal confidence in Zymeworks' future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or significant shareholders of a publicly traded company buy or sell shares; this filing indicates increased ownership by EcoR1 Capital, which is common in the biotechnology industry where investment firms often hold substantial stakes in companies they believe in.

Comparison to Industry Standards

• Comparing EcoR1's investment activity to similar biotech-focused funds like Orbimed or RA Capital Management, such increases in ownership are typical and reflect ongoing portfolio management.
• The size of the stake is significant, placing EcoR1 among the larger shareholders of Zymeworks, similar to how institutional investors often hold substantial positions in companies like Amgen or Regeneron.

Stakeholder Impact

• Increased ownership by EcoR1 Capital could be viewed positively by shareholders, potentially increasing investor confidence.
• The transactions do not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Zymeworks, EcoR1 Capital, Oleg Nodelman, Beneficial Ownership, Stock Purchase, Form 4